Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

NCT07280702 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Psoriatic Arthritis (PsA)

Interventions

DRUG: Deucravacitinib
DRUG: Placebo

Sponsor

University of Texas Southwestern Medical Center